Japanese women have lower recurrence of breast cancer

Early-stage breast cancer patients of Japanese descent that are treated with a lumpectomy and radiation therapy are more likely to be cured of their cancer than women of other ancestries, according to a new study published in the May 2005 issue of the International Journal of Radiation Oncology-Biology-Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.

The study, conducted on 896 patients treated at Kuakini Medical Center in Honolulu from 1990 to 2001, found that only six women (.67 percent) experienced a local recurrence of their breast cancer in the first six years after treatment. The patients in the study all had Tis, T1 or T2 tumors, considered early stage, with no spread to other organs or distant sites in the body. Seventy-four percent of the patients in this study were of Japanese heritage.

This figure is remarkable considering the local recurrence rates for women of all ethnicities with breast cancer published from academic centers all over the world range from two to 16 percent. Overall, the Kuakini Medical Center's survival data were superior to the National Cancer Data Base.

"This low rate of local relapse is extraordinary and unmatched by the published data results generally cited in the literature," said Mark Kanemori, M.D., lead author of the study and a radiation oncologist at Kuakini Medical Center. "This study suggests that there are biological factors that may be related to ethnicity. Hopefully, this will spark interest in the academic community to further research in this area. Identifying predictive factors of cancer biology may lead to improvements in our ability to properly select appropriate cancer treatments for our patients."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MRI-guided SBRT reduces side effects in prostate cancer treatment